SCHEMBL29426504

SCHEMBL29426504

O=c1[nH]nc(C2CC2)c2cc(Br)ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 5/20 0.42
▸ WDR77 Q9BQA1 5/20 0.42
▸ PIM1 P11309 4/20 0.38
▸ CDC7 O00311 2/20 0.38
▸ CSNK2B P67870 2/20 0.38
▸ CSNK2A1 P68400 2/20 0.38
▸ JAK2 O60674 3/20 0.38
▸ CHEK1 O14757 3/20 0.38
▸ FLT3 P36888 2/20 0.38
▸ METAP2 P50579 1/20 0.38
▸ AURKA O14965 1/20 0.38
▸ DAPK3 O43293 1/20 0.38
▸ PRKD3 O94806 1/20 0.38
▸ MAP4K4 O95819 1/20 0.38
▸ PAK4 O96013 1/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ NTRK1 P04629 1/20 0.38
▸ CSF1R P07333 1/20 0.38
▸ RET P07949 1/20 0.38
▸ MET P08581 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24076263 1.00 PRMT5 (0.42) PRMT5WDR77PIM1CDC7CSNK2B
SCHEMBL17824559 0.94 PRMT5 (0.45) PRMT5WDR77PIM1CDC7CSNK2B
SCHEMBL17824774 0.88 PRMT5 (0.46) PRMT5WDR77PIM1CDC7CSNK2B
SCHEMBL24076259 0.81 PRMT5 (0.42) PRMT5WDR77CHEK1ALDH1A1CCNA2
SCHEMBL26733229 0.81 PRMT5 (0.40) PRMT5WDR77PIM1CDC7CSNK2B
SCHEMBL29033141 0.81 PRMT5 (0.40) PRMT5WDR77PIM1CDC7CSNK2B
SCHEMBL4307495 0.79 PDPK1 (0.56) PIM1CSNK2A1JAK2CHEK1FLT3
SCHEMBL29502056 0.79 PDPK1 (0.56) CSNK2A1JAK2FLT3METAP2PRKD3
SCHEMBL11977405 0.79 PDPK1 (0.56) CSNK2A1JAK2FLT3METAP2PRKD3
SCHEMBL1789261 0.78 ATM (0.50) PRMT5ROCK1ALDH1A1POLBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 — — US disclosed
EP-4196125-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2023-06-21 — — EP disclosed
CN-116261456-A Compounds, compositions, and methods 戴纳立制药公司 2023-06-13 — — CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 — — EP disclosed
WO-2022036204-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2022-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PRMT5 2513/4885WDR77 2935/4885PIM1 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback